CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering and
developing targeted kinase medicines for patients with genomically
defined diseases, today announced the closing of its previously
announced underwritten public offering of 5,750,000 shares of its
common stock at a public offering price of $40.00 per share, including the exercise in full
by the underwriters of their option to purchase additional shares
of common stock. Blueprint Medicines estimates net proceeds from
the offering will be approximately $215.6
million, after deducting underwriting discounts and
commissions and estimated offering expenses.
Goldman, Sachs & Co., Morgan Stanley and Cowen and Company
acted as joint book-running managers for the offering. Raymond James is acting as co-manager for the
offering.
A registration statement on Form S-3 (File No. 333-216573)
relating to these securities has been previously filed with and
declared effective by the Securities and Exchange Commission (SEC).
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
A copy of the final prospectus supplement relating to the
offering has been filed with the Securities and Exchange Commission
and may be obtained from Goldman, Sachs & Co. by mail at 200
West Street, New York, New York
10282, Attention: Prospectus Department, by telephone at (866)
471-2526, or by email at prospectus-ny@ny.email.gs.com, from Morgan
Stanley & Co. LLC, Attention: Morgan Stanley Prospectus
Department, 180 Varick Street, 2nd Floor, New York, NY 10014 and from Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY 11717, Attention:
Prospectus Department, by telephone at (631) 274-2806, or by fax at
(631) 254-7140.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of targeted
and potent kinase medicines to improve the lives of patients with
genomically defined diseases. Its approach is rooted in a deep
understanding of the genetic blueprint of cancer and other diseases
driven by the abnormal activation of kinases. Blueprint Medicines
is advancing four programs in clinical development for subsets of
patients with gastrointestinal stromal tumors, hepatocellular
carcinoma, systemic mastocytosis, non-small cell lung cancer,
medullary thyroid cancer and other advanced solid tumors, as well
as multiple programs in research and preclinical development.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding the estimated net proceeds from the public offering; and
Blueprint Medicines' strategy, business plans and focus. The words
"may," "will," "could," "would," "should," "expect," "plan,"
"anticipate," "intend," "believe," "estimate," "predict,"
"project," "potential," "continue," "target" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this press
release are based on management's current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, uncertainties related to market conditions. These and
other risks and uncertainties are described in greater detail in
the section entitled "Risk Factors" in Blueprint Medicines' Annual
Report on Form 10-K for the year ended December 31, 2016, as filed with the SEC on
March 9, 2017, the prospectus
supplement related to the public offering and other filings that
Blueprint Medicines may make with the SEC in the future. Any
forward-looking statements contained in this press release
represent Blueprint Medicines' views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Blueprint Medicines explicitly disclaims any
obligation to update any forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-of-common-stock-300434472.html
SOURCE Blueprint Medicines